Leukemia Treatment in Hyderabad
Reviewed June 2026 · Dr. Madhav Danthala
Leukemia is a blood cancer that starts in the bone marrow. It is not one disease — the exact subtype decides everything. Treatment ranges from daily tablets that control the disease for decades to intensive chemotherapy and bone marrow transplant. The right plan depends on whether the leukemia is acute or chronic, and on the molecular markers found on testing.
Dr. Madhav Danthala is a hemato-oncologist and BMT physician with fellowship training in leukemia and transplant at Vancouver General Hospital, Canada. He has performed 300+ bone marrow transplants and consults at KIMS-Sunshine Hospitals, Begumpet.
Leukemia is four diseases, not one. "Acute" or "chronic" — and the molecular markers — shape the plan more than the word "leukemia" itself.
When to See a Doctor
Leukemia rarely announces itself. Its early signs are the kind people explain away — tiredness, a fever that lingers, a bruise that shouldn't be there. None of these mean leukemia on their own. The pattern that matters is when several appear together, or when a routine blood test comes back abnormal.
Tiredness and breathlessness
Persistent fatigue, pallor, or breathlessness on mild exertion can reflect anemia when leukemic cells crowd out normal red-cell production.
Easy bruising, bleeding, or petechiae
Bruises without injury, frequent nosebleeds, bleeding gums, or pinpoint red spots (petechiae) on the legs can signal a low platelet count.
Recurrent fevers and infections
Repeated infections, or a fever that keeps returning without a clear source, can occur when functioning white cells are in short supply.
An abnormal blood count
Often the first clue is incidental — a very high or very low white-cell count, or low haemoglobin and platelets, found on a blood test done for another reason.
Most of these symptoms are not leukemia. But when they persist — or a blood test is abnormal — a complete blood count and review by a hemato-oncologist is the right next step.
Understanding the Subtypes
The single most important question in leukemia is which subtype it is. It changes whether treatment is urgent or watchful, tablet-based or transplant-based.
Acute lymphoblastic leukemia (ALL)
ALL is the most common childhood cancer, but it also affects adults. It is treated with multi-drug chemotherapy protocols delivered in phases over months to a couple of years, with risk stratification by age, white-cell count, and genetics (for example, the Philadelphia chromosome, which adds a targeted TKI). Most children are cured with chemotherapy alone; adults more often need a transplant in high-risk or relapsed disease, and CD19-directed CAR-T is an option for selected relapsed B-cell ALL.
Acute myeloid leukemia (AML)
AML in adults often requires prompt, intensive induction chemotherapy to achieve remission, followed by consolidation. Genetic markers — FLT3, NPM1, IDH1/2, and cytogenetic risk — determine whether targeted drugs are added and whether an allogeneic transplant is recommended to reduce relapse. Older or less fit patients may receive lower-intensity regimens (such as venetoclax-based combinations) instead of full induction.
Chronic myeloid leukemia (CML)
CML is driven by the BCR-ABL fusion gene. Tyrosine kinase inhibitors — imatinib and newer generations — are first-line for most patients and can provide normal life expectancy with a daily tablet. Response is tracked with a quantitative BCR-ABL blood test, and transplant is reserved for resistant disease or advanced phases. Some patients in deep, sustained remission can attempt treatment-free remission under close monitoring.
Chronic lymphocytic leukemia (CLL)
CLL is often slow-growing and may need no treatment for years — "watch and wait" with regular monitoring is a legitimate plan, not neglect. When treatment is needed, modern options are largely chemo-free: BTK inhibitors (ibrutinib, acalabrutinib) and BCL-2 inhibitors (venetoclax), often with an anti-CD20 antibody. Testing for IGHV mutation status and TP53/del(17p) guides the choice.
Diagnosis — what to expect
Diagnosis starts with a complete blood count and a peripheral smear. A bone marrow aspiration and biopsy then confirm the subtype and run flow cytometry, cytogenetics (karyotype/FISH), and molecular tests that shape treatment and prognosis. These results — not the word "leukemia" alone — define the plan. See the hemato-oncology page for a step-by-step video on what a bone marrow biopsy actually involves.
Dr. Danthala's Approach
Leukemia care moves fast for acute disease and slow for chronic disease. Either way, three principles shape the plan.
-
Confirm the subtype before anything else
Flow cytometry, cytogenetics, and molecular markers are done up front. An accurate diagnosis prevents both under-treatment of aggressive disease and over-treatment of indolent disease.
-
Decide if and when transplant belongs
Not every leukemia needs a transplant, and not every patient benefits. The risk–benefit call is made early — using genetics, measurable residual disease, fitness, and donor availability — so the plan is built with the destination already in mind.
-
Track the disease with hard numbers
Response is measured, not assumed — BCR-ABL levels in CML, measurable residual disease (MRD) in acute leukemia. These numbers decide when to escalate, when to hold, and when it is safe to step back.
Treatment Options
Leukemia treatment spans a wide range — from a single daily tablet to intensive inpatient therapy and transplant. The mix is built around subtype, genetics, age, and fitness. Below are the major modalities patients should expect to discuss.
Induction, consolidation, and maintenance
For acute leukemias, chemotherapy is given in structured phases — induction to achieve remission, then consolidation (and, in ALL, maintenance) to keep it there. Regimens are intensive and usually require inpatient care with strong supportive measures.
TKIs, FLT3, IDH, and BCL-2 inhibitors
Targeted drugs attack a specific molecular driver. Imatinib and newer TKIs control CML with a daily tablet; FLT3 and IDH inhibitors are added in AML by mutation; venetoclax (a BCL-2 inhibitor) has transformed treatment for older AML patients and for CLL.
Antibodies and engineered T-cells
Antibody-based drugs (such as blinatumomab and inotuzumab in B-ALL) and CD19-directed CAR-T cell therapy have changed the outlook for relapsed or refractory B-cell ALL, offering deep remissions where chemotherapy alone has failed.
Allogeneic transplant for high-risk disease
For high-risk or relapsed acute leukemia, an allogeneic bone marrow transplant replaces diseased marrow with healthy donor stem cells and adds a graft-versus-leukemia effect. Dr. Danthala has performed 300+ transplants, including matched-sibling, unrelated-donor, and haploidentical procedures.
Transfusions, infection control, and monitoring
During intensive treatment the blood counts fall, so transfusion support, antibiotics and antifungals, and close monitoring are central to safety. Good supportive care is as much a part of curing leukemia as the chemotherapy itself.
This is the menu, not the prescription. The right plan depends on the exact subtype, genetics, age, and fitness — built with the patient in the room.
Frequently Asked Questions
Is leukemia curable?
Several leukemias are curable or controllable for many years. Most childhood ALL is cured with chemotherapy alone. CML is usually controlled long-term with a daily tyrosine kinase inhibitor tablet. AML cure rates depend on genetics, age, and response to induction — and transplant improves outcomes in high-risk cases. CLL is often a slow disease that may need no treatment for years.
When is a bone marrow transplant needed for leukemia?
Transplant is considered for many high-risk or relapsed acute leukemias, and for some chronic leukemias when standard therapy is insufficient. Eligibility depends on subtype, genetics, response to initial chemotherapy, age, and donor availability. Matched-sibling, unrelated-donor, and haploidentical transplants are all options in selected patients.
What are the warning signs of leukemia?
Persistent fatigue, unexplained fevers, easy bruising or bleeding, recurrent infections, bone pain, unintentional weight loss, or abnormal counts on a routine blood test. Many of these symptoms are non-specific — diagnosis requires blood tests and often a bone marrow biopsy.
Is CML the same as the other leukemias?
No. CML is driven by a single, well-understood gene (BCR-ABL) and for most patients is controlled with a daily tablet rather than intensive chemotherapy — many live a normal lifespan. That is very different from acute leukemias (ALL, AML), which usually need prompt, intensive treatment. This is exactly why confirming the subtype matters so much.
How do I book a leukemia consultation in Hyderabad?
Book at KIMS-Sunshine Begumpet via KIMS Hospitals (kimshospitals.com) or KIMS Sunshine (kimssunshine.co.in). Room 545, 5th Floor OPD, Mon–Sat 10 AM–5 PM. There is also an evening clinic at Peoples Polyclinic, Manikonda — call +91 9346524080. A second opinion is welcome, especially before starting intensive treatment.
About Dr. Madhav Danthala
Dr. Madhav Danthala is a hemato-oncologist and bone marrow transplant physician at KIMS-Sunshine Hospitals, Begumpet, Hyderabad. He holds a DM in Medical Oncology from NIMS and completed fellowship training in leukemia and bone marrow transplant at Vancouver General Hospital, Canada. He has performed 300+ stem cell transplants and focuses on acute and chronic leukemias, lymphoma, myeloma, transplant, and second opinions.
Trusted guidelines & further reading
- Leukemia & Lymphoma Society — Leukemia Patient information on each leukemia subtype, treatment, and support.
- NCI / Cancer.gov — Leukemia US National Cancer Institute treatment summaries for ALL, AML, CML, and CLL.
- ASCO / Cancer.Net — Leukemia American Society of Clinical Oncology patient education portal.